• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sonendo Inc.

    3/16/23 3:28:29 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care
    Get the next $SONX alert in real time by email
    SC 13G 1 tm239676d1_sc13g.htm SC 13G

     

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.__)*

     

     

    Sonendo, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    835431107

    (CUSIP Number)

     

    September 27, 2022

    (Date of Event Which Requires Filing this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b) 

     

    x Rule 13d-1(c) 

     

    ¨ Rule 13d-1(d) 

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 2 of 9

     

    1.

    NAMES OF REPORTING PERSONS

     

    JMR Capital Limited

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ¨ (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,021,605

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,021,605

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,021,605

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.973%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 3 of 9

     

    1.

    NAMES OF REPORTING PERSONS

     

    FTA Global Holdings, Ltd.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)¨ (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,021,605 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,021,605 (1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,021,605 (1)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.973%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    (1)All of these shares of the Common Stock, par value $0.001 per share (“Common Stock”), of Sonendo, Inc. may be deemed to be beneficially owned by FTA Global Holdings, Ltd. in its capacity as the sole shareholder of JMR Capital Limited.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 4 of 9

     

    1.

    NAMES OF REPORTING PERSONS

     

    William Randall Work

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)¨ (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ireland

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,021,605 (2)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,021,605 (2)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,021,605 (2)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.973%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    (2)All of these shares of Common Stock may be deemed to be beneficially owned by Mr. Work in his capacity as sole shareholder of FTA Global Holdings, Ltd.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 5 of 9

     

    Item 1(a)Name of Issuer:

     

    Sonendo, Inc. (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    26061 Merit Circle, Suite 102

    Laguna Hills, California 92653

     

    Item 2(a)-(c)Name of Persons Filing; Address of Principal Business Office; Citizenship

     

    This Schedule 13G is filed jointly by each of the following persons (each a “Reporting Person” and, collectively, as the “Reporting Persons”):

     

    1.JMR Capital Limited, an exempted company limited by shares and organized under the laws of Bermuda (“JMR”), in JMR’s capacity as the direct owner of 3,021,605 shares of the Issuer’s common stock, par value $0.001 per share (“Common Stock”);

     

    2.FTA Global Holdings, Ltd., an exempted company limited by shares and organized under the laws of Bermuda (“FTA”), in FTA’s capacity as the sole shareholder of JMR; and

     

    3.William Randall Work, a citizen of Ireland (“Mr. Work”), in Mr. Work’s capacity as the sole shareholder of FTA.

     

    Each of JMR’s and FTA’s principal business office address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. Mr. Work’s principal business office address is Flat 1-2, 17 Belgrave Place, London SW1X 8BS, United Kingdom.

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e)CUSIP No.:

     

    835431107

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b)  ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c)  ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); 
         
    (d)  ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 6 of 9

     

     

    (e)  ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f)  ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g)  ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h)  ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
         
    (j)  ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
         
    (k)  ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Item 4. Ownership:

     

    Information with respect to each Reporting Person’s ownership as of the date hereof is incorporated by reference to items (5) - (9) and (11) of the cover page for such Reporting Person.

     

    The percentages used in this Schedule 13G are calculated based upon the Issuer’s 50,583,550 issued and outstanding shares of Common Stock, as reported by the Issuer in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2023.

     

    Pursuant to Rule 13d-4 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons declare that filing this Schedule 13G shall not be construed as an admission that any such person is, for the purposes of Section 13(d) and/or Section 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Schedule 13G except to the extent of such person’s pecuniary interest in the Common Stock, and except to the extent of its pecuniary interest, such beneficial ownership is expressly disclaimed by each Reporting Person.

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 7 of 9

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 8 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 16, 2023

     

      JMR CAPITAL LIMITED
       
      By: /s/ Louis Paletta
      Name: Louis Paletta
      Title:   Vice President
       
      FTA GLOBAL HOLDINGS, LTD.
       
      By: /s/ Louis Paletta
      Name: Louis Paletta
      Title:   Vice President
       
      By: /s/ William Randall Work
      Name: William Randall Work

     

     

     

     

      SCHEDULE 13G  
         
    CUSIP No. 835431107   Page 9 of 9

     

    Exhibit 1

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. 

     

    Dated: March 16, 2023

     

      JMR CAPITAL LIMITED
       
      By: /s/ Louis Paletta
      Name: Louis Paletta
      Title:   Vice President
       
      FTA GLOBAL HOLDINGS, LTD.
       
      By: /s/ Louis Paletta
      Name: Louis Paletta
      Title:   Vice President
       
      By: /s/ William Randall Work
      Name: William Randall Work

     

     

     

    Get the next $SONX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SONX

    DatePrice TargetRatingAnalyst
    3/12/2024Buy → Hold
    Stifel
    1/31/2022$6.90Equal-Weight
    Morgan Stanley
    11/23/2021$16.00Buy
    Stifel
    11/23/2021$15.00Buy
    B of A Securities
    11/23/2021$30.00Buy
    Goldman Sachs
    11/23/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $SONX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP Operations Mcgaugh John P. was granted 500,000 shares, increasing direct ownership by 142% to 852,896 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:48:44 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bostjancic John J. was granted 600,000 shares, increasing direct ownership by 83% to 1,320,000 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:46:24 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • President and CEO Bergheim Bjarne was granted 1,600,000 shares, increasing direct ownership by 85% to 3,488,518 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      9/19/24 5:42:53 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    SEC Filings

    See more
    • SEC Form D filed by Sonendo Inc.

      D - Sonendo, Inc. (0001407973) (Filer)

      5/12/25 1:21:37 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Sonendo Inc.

      10-K - Sonendo, Inc. (0001407973) (Filer)

      3/26/25 4:06:45 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Sonendo Inc.

      EFFECT - Sonendo, Inc. (0001407973) (Filer)

      2/28/25 12:15:03 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Financials

    Live finance-specific insights

    See more
    • Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

      Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

      11/11/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

      Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th

      10/29/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

      Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv

      8/7/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

      SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

      11/14/24 4:40:34 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sonendo Inc.

      SC 13G - Sonendo, Inc. (0001407973) (Subject)

      11/14/24 1:23:43 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sonendo Inc. (Amendment)

      SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

      2/14/24 5:15:11 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care

    $SONX
    Leadership Updates

    Live Leadership Updates

    See more

    $SONX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SONX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SONX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sonendo Strengthens Leadership With Key Strategic Appointments

      John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil

      6/5/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment

      The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a

      10/4/23 8:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

      Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p

      9/26/23 8:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Mcgaugh John P. bought $11,545 worth of shares (116,500 units at $0.10), increasing direct ownership by 47% to 363,797 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/23/24 6:05:19 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Bergheim Olav bought $49,504 worth of shares (520,000 units at $0.10) (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/17/24 2:30:11 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Pudipeddi Vamsi Mohan Raj bought $47,000 worth of shares (500,000 units at $0.09), increasing direct ownership by 27% to 2,374,498 units (SEC Form 4)

      4 - Sonendo, Inc. (0001407973) (Issuer)

      5/14/24 5:18:33 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Announces $5.0 Million Private Placement

      Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock, resulting in gross proceeds of $5.0 million (the "Private Placement"). New and existing investors, including certain directors and officers of the Company, participated in the financing. Sonendo intends to use the proceeds from the financing to expand commercial programs to drive revenue growth, continue executing ongoing business restructuring activities to further reduce operating expenses and accelerate the path to positive adjusted EBITDA and operating cash flow, to retain senior leadership and key emplo

      5/1/25 6:00:00 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2024. Quarterly Highlights Generated $8.3 million total revenue for the fourth quarter 2024; Drove substantial 1,570 and 1,260 basis points of GAAP and adjusted (non-GAAP) gross margin expansion for the fourth quarter 2024 to 41.1% and 41.3%, respectively, as compared to the prior year quarter; Significantly reduced GAAP operating loss to $5.6 million and adjusted EBITDA (non-GAAP) loss to $4.7 million for the fourth quarter 2024, an improvement of 45.2% and 45.0%, respectively,

      3/26/25 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo, Inc. Reports Third Quarter 2024 Financial Results

      Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and

      11/12/24 4:05:00 PM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Sonendo downgraded by Stifel

      Stifel downgraded Sonendo from Buy to Hold

      3/12/24 7:33:34 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Sonendo with a new price target

      Morgan Stanley initiated coverage of Sonendo with a rating of Equal-Weight and set a new price target of $6.90

      1/31/22 7:34:46 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Sonendo with a new price target

      Stifel initiated coverage of Sonendo with a rating of Buy and set a new price target of $16.00

      11/23/21 7:43:50 AM ET
      $SONX
      Medical/Dental Instruments
      Health Care